Abstract
This review provides a comprehensive analysis of the transformative impact of artificial intelligence (AI) and machine learning (ML) on modern drug design, specifically focusing on how these advanced computational techniques address the inherent limitations of traditional small-molecule drug design methodologies. It begins by outlining the historical challenges of the drug discovery pipeline, including protracted timelines, exorbitant costs, and high clinical failure rates. Subsequently, it examines the core principles of structure-based virtual screening (SBVS) and ligand-based virtual screening (LBVS), establishing the critical bottlenecks that have historically impeded efficient drug development. The central sections elucidate how cutting-edge ML and deep learning (DL) paradigms, such as generative models and reinforcement learning, are revolutionizing chemical space exploration, enhancing binding affinity prediction, improving protein flexibility modeling, and automating critical design tasks. Illustrative real-world case studies demonstrating quantifiable accelerations in discovery timelines and improved success probabilities are presented. Finally, the review critically examines prevailing challenges, including data quality, model interpretability, ethical considerations, and evolving regulatory landscapes, while offering forward-looking critical perspectives on the future trajectory of AI-driven pharmaceutical innovation.